Unity Biotechnology is a biotechnology company engaged in researching and developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. Co.'s focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic and neurologic diseases. Co.'s ophthalmology program includes UBX1325, which is Co.'s main drug candidate for age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Co.'s neurology program includes UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain. The UBX stock yearly return is shown above.
The yearly return on the UBX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the UBX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|